Overlapping area represents amount of risk that can be diversified away by holding Biovail Corp. Common Stoc and The Quigley Corp. in the same portfolio (assuming nothing else is changed)
Valeant Pharmaceuticals International, Inc. raised bidding price from $6.50 to $7.50 per share in cash relevant to its earlier proposed price for the acquisition of ISTA Pharmaceuticals.
Philadelphia Business Journal (blog) - Feb 7, 2012
Cold-Eeze maker ProPhase Labs Inc. says it is a defendant in a complaint filed by stockholder and former CEO Guy Quigley. Company founder Quigley lost a takeover battle orchestrated by a group of stockholders two years ago.
USA 
Select Assests
Optimize Portfolio
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatilities
Import Equities
Search Equities
Filter Tops
Biovail Corp. Common Stoc and 
The Quigley Corp.
